Olivier Wong

Olivier is a seasoned expert in HTA and Market Access, with over 20 years of experience at the intersection of clinical practice, policy, and pharma. He served for 13 years as a voting member of France’s Commission de la Transparence—the national HTA and reimbursement body influencing access decisions for a €29 billion healthcare budget. He was also a long-standing academic physician and member of France’s National Guideline Committees within both the Drug Agency and the National Health Authority.​

Earlier in his career, Olivier worked in drug development at Hoechst and Behringwerke AG and has since advised numerous Ministries of Health and payer organizations on disease management and access strategy, particularly in rare diseases. He is a frequent lecturer at global institutions (LSE, Peking University, Fudan University) and a trusted voice in international HTA and payer forums, as well as Board of Directors meetings, drawing on a decade of experience across hundreds of strategic advisory boards.